- JP-listed companies
- Tri Chemical Laboratories Inc.
- Income statement
Tri Chemical Laboratories Inc.JP:4369
Market cap
¥84.4B
P/E ratio
17.6x
| 2012/01 | 2013/01 | 2014/01 | 2015/01 | 2016/01 | 2017/01 | 2018/01 | 2019/01 | 2020/01 | 2021/01 | 2022/01 | 2023/01 | 2024/01 | 2025/01 | |
| Revenue | 4,002 | 3,218 | 3,362 | 4,103 | 4,957 | 5,470 | 6,446 | 7,792 | 8,267 | 9,801 | 11,574 | 13,803 | 11,246 | 18,905 |
| Revenue growth (%) | - | |||||||||||||
| Cost of revenue | - | - | - | 2,671 | 3,046 | 3,297 | 3,559 | 4,200 | 4,315 | 5,421 | 6,739 | 8,224 | 7,160 | 10,894 |
| Gross profit | - | - | - | 1,432 | 1,910 | 2,173 | 2,887 | 3,592 | 3,953 | 4,381 | 4,835 | 5,579 | 4,086 | 8,012 |
| Gross margin (%) | - | - | - | |||||||||||
| Operating margin (%) | - | - | - | |||||||||||
| Operating income | - | - | - | 351 | 722 | 977 | 1,598 | 2,153 | 2,327 | 2,691 | 2,976 | 3,504 | 1,947 | 5,256 |
| Operating expenses | - | - | - | 1,081 | 1,189 | 1,196 | 1,289 | 1,439 | 1,626 | 1,690 | 1,859 | 2,075 | 2,138 | 2,756 |
| Income before tax | 290 | 61 | 53 | 426 | 694 | 975 | 1,623 | 2,932 | 3,744 | 4,323 | 5,294 | 6,186 | 3,276 | 6,583 |
| Pretax margin (%) | 7.2 | 1.9 | 1.6 | 10.4 | 14 | 17.8 | 25.2 | 37.6 | 45.3 | 44.1 | 45.7 | 44.8 | 29.1 | 34.8 |
| Provision for income taxes | - | - | - | 216 | 220 | 351 | 479 | 664 | 804 | 946 | 1,200 | 1,354 | 806 | 1,621 |
| Effective tax rate (%) | - | - | - | |||||||||||
| Net income | 175 | 16 | 68 | 361 | 473 | 767 | 1,146 | 2,267 | 2,940 | 3,377 | 4,095 | 4,832 | 2,471 | 4,331 |
| Net income margin (%) | ||||||||||||||
| Earnings per share | 24.67 | 2.18 | 9.4 | 49.45 | 61.77 | 98.3 | 146.65 | 290.23 | 376.33 | 108.08 | 126.33 | 148.7 | 76.03 | 152.69 |
| Diluted EPS | 23.51 | 2.18 | 9.39 | 48.01 | 60.88 | 98.3 | 146.65 | 290.23 | 376.33 | 108.08 | 126.33 | 148.7 | 76.03 | 152.69 |
| Dividend payout ratio (%) | - | |||||||||||||
| Dividend per share | 5 | - | 2 | 7 | 10 | 16 | 21 | 45 | 58 | 68 | 20 | 30 | 30 | 35 |
| EBITDA | - | - | - | |||||||||||
| EBITDA margin (%) | - | - | - |